Publication: Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes
No Thumbnail Available
Identifiers
Date
2016-08-01
Authors
Wolffenbuttel, B. H. R.
Van Gaal, L.
Duran-Garcia, S.
Han, J.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Wiley
Metrics
Export
Abstract
This post hoc analysis assessed the evidence behind common reimbursement practices by evaluating the relationship of body mass index (BMI) ranges (35 kg/m(2)) with treatment effects of exenatide twice daily among patients with type 2 diabetes. Patients received exenatide twice daily added to insulin glargine in two 30-week studies (exenatide twice daily vs insulin lispro, n = 627; exenatide twice daily vs placebo, n = 259). No association of baseline BMI with changes in efficacy variables was observed. Glycated haemoglobin (HbA1c) reductions were significant (p
Description
MeSH Terms
DeCS Terms
CIE Terms
Keywords
body mass index, exenatide twice daily, type 2 diabetes, Peptide-1 receptor agonist, Basal insulin, Bolus insulin, Safety, Liraglutide, Management, Degludec